overview corporate governance strategy history people contact news register careers
manufacturing quality regulatory
product licensing opportunities ip licensing opportunities
products in development
financial reports financial calendar corporate advisers share information admission documents shareholder circulars
financial regulatory industry

IP LICENSING OPPORTUNITIES

GeneMedix has a dual strategy of commercialising therapeutic proteins that are not patented, whilst applying for its own patents on novel genes and proteins arising from research at the Shanghai Institute of Biochemistry and Cell Biology.

GeneMedix is pursuing the following international patent applications:

Monomeric Analogues of Human Insulin (WO0118052)

monomeric insulin

This patent claims human insulin variants that have amino acid substitutions in the 16 and 26 position of the B chain. These variants exist as monomers that have a faster therapeutic action than older insulin products.

This patent has issued in two countries, namely Australia, Patent No 767006, and the USA, Patent No 6800606.

The market for human insulin is about $4 bn worldwide, with monomeric products representing one of the fastest growing sectors.

A Novel Monomeric Insulin [PCT/GB2003/003136]

This patent claims novel truncated insulin sequences and a novel precursor molecule for their production. The market for human insulin is about $4 bn worldwide, with monomeric products representing one of the fastest growing sectors.

If you have an interest in licensing intellectual property rights please contact: